cetirizine has been researched along with Itching in 53 studies
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.
cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The histamine H4 receptor (H4R) is a promising target for the treatment of pruritus." | 9.19 | The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. ( Chen, B; Dunford, PJ; Francke, K; Greenspan, AJ; Kollmeier, A; Thurmond, RL; Xia, Y; Xu, XL; Zhou, B, 2014) |
| "The efficacy of OH was noninferior to that of cetirizine in controlling itching indicating that it can be considered as a clinically relevant alternative therapy to cetirizine for the management of CP in adult Chinese patients." | 9.17 | A multicenter, double-blind, randomized, noninferiority comparison of 14 days' treatment with oral olopatadine 10 mg or cetirizine 10 mg in Chinese adults with cutaneous pruritus. ( Li, M; Lian, S; Liu, Y; Wang, T; Yin, J; Zeng, F; Zhang, S; Zheng, Z, 2013) |
| " Efficacy and safety of doubling the dose of cetirizine were compared with olopatadine in the patients with symptoms like wheal or itching, despite the treatment with the standard dose of cetirizine." | 9.17 | Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. ( Okubo, Y; Shigoka, Y; Tsuboi, R; Yamazaki, M, 2013) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 9.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "A 4-week randomized, double-blind safety and efficacy study was conducted to compare the safety and efficacy of cetirizine, doxepine, and hydroxyzine 5 in the treatment of chronic pruritus due to sulfur mustard." | 9.12 | Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. ( Davoudi, SM; Keshavarz, S; Sadr, B; Shohrati, M; Tajik, A, 2007) |
| " Levocetirizine administered once daily is effective and well tolerated in the treatment of the symptoms of chronic idiopathic urticaria and in improving the patient's quality of life." | 9.12 | Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Barra, L; Colanardi, MC; Ferrannini, A; Nettis, E; Tursi, A; Vacca, A, 2006) |
| "Histamine and serotonin are no major mediators of pruritus in hemodialysis patients." | 9.10 | Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy. ( Domröse, U; Dunker, N; Gollnick, H; Neumann, KH; Weisshaar, E, 2003) |
| "Compared with that before treatment, the itching degree of patients with light, moderate, and severe itching in placebo group was not relieved after treatment; the itching degree of patients with moderate or severe itching in cetirizine group was alleviated after treatment, but not in patients with light itching; itching degree of all patients in gabapentin group was significantly relieved after treatment." | 7.81 | [Clinical effects of gabapentin on the treatment of pruritus of scar resulting from deep partial-thickness burn]. ( Bing, Z; Qiang, W; Wei, L; Zheng, L, 2015) |
| "While histamine is the crucial mediator of pruritus in type 1 allergic reactions, its role in atopic dermatitis (AD) is unclear." | 7.70 | Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. ( Heyer, G; Lischetzki, G; McGlone, F; Rukwied, R; Schmelz, M, 2000) |
| " Drug dosage was determined by initial VAS (visual analog scale) scores." | 6.78 | A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. ( Ahuja, RB; Gupta, GK, 2013) |
| "Post-burn pruritis is a very distressing symptom having a reported incidence between 80 and 100%." | 6.76 | A comparative analysis of cetirizine, gabapentin and their combination in the relief of post-burn pruritus. ( Ahuja, RB; Gupta, G; Gupta, R; Shrivastava, P, 2011) |
| "Pruritus was reduced in 41% (13/32) of the cats." | 5.38 | An open clinical trial on the efficacy of cetirizine hydrochloride in the management of allergic pruritus in cats. ( Griffin, JS; Miller, WH; Scott, DW; Tranchina, MM, 2012) |
| "The histamine H4 receptor (H4R) is a promising target for the treatment of pruritus." | 5.19 | The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. ( Chen, B; Dunford, PJ; Francke, K; Greenspan, AJ; Kollmeier, A; Thurmond, RL; Xia, Y; Xu, XL; Zhou, B, 2014) |
| "The efficacy of OH was noninferior to that of cetirizine in controlling itching indicating that it can be considered as a clinically relevant alternative therapy to cetirizine for the management of CP in adult Chinese patients." | 5.17 | A multicenter, double-blind, randomized, noninferiority comparison of 14 days' treatment with oral olopatadine 10 mg or cetirizine 10 mg in Chinese adults with cutaneous pruritus. ( Li, M; Lian, S; Liu, Y; Wang, T; Yin, J; Zeng, F; Zhang, S; Zheng, Z, 2013) |
| " Efficacy and safety of doubling the dose of cetirizine were compared with olopatadine in the patients with symptoms like wheal or itching, despite the treatment with the standard dose of cetirizine." | 5.17 | Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. ( Okubo, Y; Shigoka, Y; Tsuboi, R; Yamazaki, M, 2013) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 5.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "A 4-week randomized, double-blind safety and efficacy study was conducted to compare the safety and efficacy of cetirizine, doxepine, and hydroxyzine 5 in the treatment of chronic pruritus due to sulfur mustard." | 5.12 | Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. ( Davoudi, SM; Keshavarz, S; Sadr, B; Shohrati, M; Tajik, A, 2007) |
| " Levocetirizine administered once daily is effective and well tolerated in the treatment of the symptoms of chronic idiopathic urticaria and in improving the patient's quality of life." | 5.12 | Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Barra, L; Colanardi, MC; Ferrannini, A; Nettis, E; Tursi, A; Vacca, A, 2006) |
| "Histamine and serotonin are no major mediators of pruritus in hemodialysis patients." | 5.10 | Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy. ( Domröse, U; Dunker, N; Gollnick, H; Neumann, KH; Weisshaar, E, 2003) |
| "This comparative study in mosquito-bite-sensitive adults shows that cetirizine and ebastine decrease significantly whealing and accompanying pruritus, and that cetirizine seems to be the most effective against pruritus." | 5.10 | Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. ( Burri, P; Karppinen, A; Kautiainen, H; Petman, L; Reunala, T, 2002) |
| " However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares." | 5.01 | Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. ( Apfelbacher, CJ; Böhmer, MM; Carter, B; Jupiter, A; Matterne, U; Weisshaar, E, 2019) |
| "Compared with that before treatment, the itching degree of patients with light, moderate, and severe itching in placebo group was not relieved after treatment; the itching degree of patients with moderate or severe itching in cetirizine group was alleviated after treatment, but not in patients with light itching; itching degree of all patients in gabapentin group was significantly relieved after treatment." | 3.81 | [Clinical effects of gabapentin on the treatment of pruritus of scar resulting from deep partial-thickness burn]. ( Bing, Z; Qiang, W; Wei, L; Zheng, L, 2015) |
| "While histamine is the crucial mediator of pruritus in type 1 allergic reactions, its role in atopic dermatitis (AD) is unclear." | 3.70 | Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. ( Heyer, G; Lischetzki, G; McGlone, F; Rukwied, R; Schmelz, M, 2000) |
| " The antipruritic effect of tropisetron reported in cholestatic and uremic pruritus could not be verified in healthy persons under experimental conditions." | 3.69 | Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? ( Gollnick, H; Weisshaar, E; Ziethen, B, 1997) |
| " These results suggest that double-dosed levocetirizine treatment suppresses histamine-induced skin symptoms more rapidly, profoundly and sustainably than conventionally dosed levocetirizine treatment." | 2.78 | A double dose of levocetirizine leads to better control of histamine-induced flare, wheal and itch in healthy donors. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Nakamizo, S; Tanizaki, H, 2013) |
| "Levocetirizine was more inhibitory than fexofenadine on wheal, flare and pruritus (p < 0." | 2.78 | The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. ( Church, MK; Maurer, M; Schoepke, N, 2013) |
| " Drug dosage was determined by initial VAS (visual analog scale) scores." | 2.78 | A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. ( Ahuja, RB; Gupta, GK, 2013) |
| "Post-burn pruritis is a very distressing symptom having a reported incidence between 80 and 100%." | 2.76 | A comparative analysis of cetirizine, gabapentin and their combination in the relief of post-burn pruritus. ( Ahuja, RB; Gupta, G; Gupta, R; Shrivastava, P, 2011) |
| "Levocetirizine treatment also correlated with a significant increase in the percentage of CD4+CD25+ T cells (P<0." | 2.73 | Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. ( Arifhodzic, N; Haines, D; Mahmoud, F; Novotney, L, 2008) |
| "Levocetirizine was used as a comparator." | 2.71 | Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ( Boutsiouki, P; Church, MK; Clough, GF; Denham, KJ, 2003) |
| "Pruritus was induced by iontophoresis with serotonin and histamine and recorded before and after HD." | 2.71 | Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. ( Dunker, N; Gollnick, H; Röhl, FW; Weisshaar, E, 2004) |
| "Nasal obstruction is the main symptom in patients with persistent allergic rhinitis." | 2.71 | Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. ( Ciprandi, G; Cirillo, IG; Tosca, MA; Vizzaccaro, A, 2005) |
| "Cetirizine (5 mg) was ingested three times a week during the predialysis period." | 2.70 | Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. ( Fujita, T; Nakao, A; Noiri, E; Ozawa, H, 2001) |
| "Azelastine was superior to cetirizine in reducing pruritus, whereas cetirizine caused a more marked reduction of whealing." | 2.69 | Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. ( Henz, BM; Metzenauer, P; O'Keefe, E; Zuberbier, T, 1998) |
| "In contrast, controls reported a burning pain after the injection of ACh, whereas AE patients felt predominantly pruritus." | 2.69 | Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. ( Heyer, G; Rukwied, R, 1999) |
| " black triangle The bioavailability of cetirizine and pseudoephedrine is similar after administration of cetirizine/pseudoephedrine 5/120 mg bilayer tablets or coadministration of cetirizine 5 mg tablets plus pseudoephedrine sustained-release (SR) 120 mg caplets." | 2.41 | Cetirizine/pseudoephedrine. ( Jarvis, B; Wellington, K, 2001) |
| "Levocetirizine is a second-generation nonsedative antihistaminic agent that has been demonstrated to be safe and effective for treating allergic disease." | 1.43 | A case of levocetirizine-induced liver injury. ( Cho, JY; Jung, MC; Kim, JK; Kim, SE; Lee, B; Park, JW; Seo, J; Song, JW, 2016) |
| "Pruritus was reduced in 41% (13/32) of the cats." | 1.38 | An open clinical trial on the efficacy of cetirizine hydrochloride in the management of allergic pruritus in cats. ( Griffin, JS; Miller, WH; Scott, DW; Tranchina, MM, 2012) |
| "Cetirizine and placebo were administered orally as individual agents to 23 dogs with atopic dermatitis." | 1.32 | Treatment of canine atopic dermatitis with cetirizine, a second generation antihistamine: a single-blinded, placebo-controlled study. ( Cobb, SM; Cook, CP; Kirker, JE; Miller, WH; Scott, DW, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.89) | 18.7374 |
| 1990's | 6 (11.32) | 18.2507 |
| 2000's | 22 (41.51) | 29.6817 |
| 2010's | 21 (39.62) | 24.3611 |
| 2020's | 3 (5.66) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Mueller, SM | 2 |
| Navarini, AA | 2 |
| Goldust, M | 2 |
| Brandt, O | 2 |
| Griffiths, CEM | 2 |
| Kleyn, CE | 2 |
| Kassem, MA | 1 |
| Ghalwash, MM | 1 |
| Abdou, EM | 1 |
| Brás, S | 1 |
| Oliveira, A | 1 |
| Mendes-Bastos, P | 1 |
| Amaro, C | 1 |
| Matterne, U | 1 |
| Böhmer, MM | 1 |
| Weisshaar, E | 4 |
| Jupiter, A | 1 |
| Carter, B | 1 |
| Apfelbacher, CJ | 1 |
| Tanizaki, H | 1 |
| Nakamizo, S | 1 |
| Nakahigashi, K | 1 |
| Miyachi, Y | 1 |
| Kabashima, K | 1 |
| Takeo, T | 1 |
| Kasugai, C | 1 |
| Tanaka, R | 1 |
| Ando, T | 1 |
| Ogawa, A | 1 |
| Akita, Y | 1 |
| Watanabe, D | 1 |
| Cohen, PR | 1 |
| Kurzrock, R | 1 |
| Kollmeier, A | 1 |
| Francke, K | 1 |
| Chen, B | 1 |
| Dunford, PJ | 1 |
| Greenspan, AJ | 1 |
| Xia, Y | 1 |
| Xu, XL | 1 |
| Zhou, B | 1 |
| Thurmond, RL | 1 |
| Zakaria, K | 1 |
| Zheng, L | 1 |
| Bing, Z | 1 |
| Wei, L | 1 |
| Qiang, W | 1 |
| Jung, MC | 1 |
| Kim, JK | 1 |
| Cho, JY | 1 |
| Song, JW | 1 |
| Lee, B | 1 |
| Park, JW | 1 |
| Seo, J | 1 |
| Kim, SE | 1 |
| Ebid, AA | 1 |
| Ibrahim, AR | 1 |
| Omar, MT | 1 |
| El Baky, AMA | 1 |
| Yokota, E | 1 |
| Kuyama, S | 1 |
| Sugimoto, Y | 1 |
| Ogawa, M | 1 |
| Kamei, C | 2 |
| Mahmoud, F | 1 |
| Arifhodzic, N | 1 |
| Haines, D | 1 |
| Novotney, L | 1 |
| Potter, PC | 1 |
| Kapp, A | 1 |
| Maurer, M | 2 |
| Guillet, G | 1 |
| Jian, AM | 1 |
| Hauptmann, P | 1 |
| Finlay, AY | 1 |
| Zhu, Y | 2 |
| Peng, C | 2 |
| Xu, JG | 2 |
| Liu, YX | 2 |
| Zhu, QG | 2 |
| Liu, JY | 2 |
| Li, FQ | 2 |
| Wu, JH | 1 |
| Hu, JH | 2 |
| Wang, XR | 1 |
| Wu, L | 1 |
| Pan, YH | 1 |
| You, BM | 1 |
| Ahuja, RB | 2 |
| Gupta, R | 1 |
| Gupta, G | 1 |
| Shrivastava, P | 1 |
| Prieto de Paula, JM | 1 |
| Franco Hidalgo, S | 1 |
| Nalotto, L | 1 |
| Ginés Santiago, A | 1 |
| Gokdemir, G | 1 |
| Doruk, T | 1 |
| Zhong, J | 1 |
| Xian, D | 1 |
| Xu, Y | 1 |
| Liu, J | 1 |
| Okubo, Y | 1 |
| Shigoka, Y | 1 |
| Yamazaki, M | 1 |
| Tsuboi, R | 1 |
| Pfab, F | 1 |
| Kirchner, MT | 1 |
| Huss-Marp, J | 1 |
| Schuster, T | 1 |
| Schalock, PC | 1 |
| Fuqin, J | 1 |
| Athanasiadis, GI | 1 |
| Behrendt, H | 1 |
| Ring, J | 1 |
| Darsow, U | 1 |
| Napadow, V | 1 |
| Griffin, JS | 1 |
| Scott, DW | 2 |
| Miller, WH | 2 |
| Tranchina, MM | 1 |
| Gupta, GK | 1 |
| Schoepke, N | 1 |
| Church, MK | 2 |
| Wang, T | 1 |
| Liu, Y | 1 |
| Yin, J | 1 |
| Lian, S | 1 |
| Li, M | 1 |
| Zheng, Z | 1 |
| Zeng, F | 1 |
| Zhang, S | 1 |
| Dunker, N | 2 |
| Domröse, U | 1 |
| Neumann, KH | 1 |
| Gollnick, H | 3 |
| Breugelmans, JG | 1 |
| Bosman, A | 1 |
| van der Heide, AK | 1 |
| Roeleveld-Kuijper, EY | 1 |
| Bruynzeel, DP | 1 |
| Denham, KJ | 1 |
| Boutsiouki, P | 1 |
| Clough, GF | 1 |
| Ciprandi, G | 2 |
| Tosca, MA | 2 |
| Milanese, M | 1 |
| Schenone, G | 1 |
| Ricca, V | 1 |
| Röhl, FW | 1 |
| Cook, CP | 1 |
| Kirker, JE | 1 |
| Cobb, SM | 1 |
| Minami, K | 1 |
| Fujii, Y | 1 |
| Cirillo, IG | 1 |
| Vizzaccaro, A | 1 |
| Nettis, E | 1 |
| Colanardi, MC | 1 |
| Barra, L | 1 |
| Ferrannini, A | 1 |
| Vacca, A | 1 |
| Tursi, A | 1 |
| Karppinen, A | 2 |
| Brummer-Korvenkontio, H | 1 |
| Petman, L | 2 |
| Kautiainen, H | 2 |
| Hervé, JP | 1 |
| Reunala, T | 2 |
| Green, WH | 1 |
| Yosipovitch, G | 1 |
| Pichardo, RO | 1 |
| Shohrati, M | 1 |
| Davoudi, SM | 1 |
| Keshavarz, S | 1 |
| Sadr, B | 1 |
| Tajik, A | 1 |
| Day, JH | 1 |
| Briscoe, MP | 1 |
| Clark, RH | 1 |
| Ellis, AK | 1 |
| Gervais, P | 1 |
| Ziethen, B | 1 |
| Henz, BM | 2 |
| Metzenauer, P | 1 |
| O'Keefe, E | 1 |
| Zuberbier, T | 1 |
| Lippert, U | 1 |
| Hoer, A | 1 |
| Möller, A | 1 |
| Ramboer, I | 1 |
| Cremer, B | 1 |
| Rukwied, R | 2 |
| Heyer, G | 2 |
| Phillips, RL | 1 |
| Koenig, CJ | 1 |
| Lischetzki, G | 1 |
| McGlone, F | 1 |
| Schmelz, M | 1 |
| Noiri, E | 1 |
| Ozawa, H | 1 |
| Fujita, T | 1 |
| Nakao, A | 1 |
| Wellington, K | 1 |
| Jarvis, B | 1 |
| Burri, P | 1 |
| Coulie, P | 1 |
| Wery, M | 1 |
| Ghys, L | 1 |
| Rihoux, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response[NCT01586091] | Phase 4 | 18 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this. (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | mm (Mean) |
|---|---|
| Placebo | 69.4 |
| Levocetirizin | 20.4 |
| Fexofenadine | 39.9 |
"We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a 0 and 100 at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point." (NCT01586091)
Timeframe: up to 10 minutes after skin prick test performed 24 hours after drug administration
| Intervention | mm (Mean) |
|---|---|
| Levocetirizin | 11.5 |
| Fexofenadine | 25.4 |
| Placebo | 46.0 |
Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany). (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | cm3 (Mean) |
|---|---|
| Placebo | 174.6 |
| Levocetirizin | 35.2 |
| Fexofenadine | 106.3 |
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
2 reviews available for cetirizine and Itching
| Article | Year |
|---|---|
Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.
Topics: Administration, Oral; Administration, Topical; Adult; Cetirizine; Chemotherapy, Adjuvant; Child; Ecz | 2019 |
Cetirizine/pseudoephedrine.
Topics: Administration, Oral; Adrenergic Agents; Anxiety; Asthenia; Biological Availability; Cetirizine; Che | 2001 |
28 trials available for cetirizine and Itching
| Article | Year |
|---|---|
A double dose of levocetirizine leads to better control of histamine-induced flare, wheal and itch in healthy donors.
Topics: Adult; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female | 2013 |
Evaluation of the antihistamine effects of olopatadine and levocetirizine during a 24-h period: a double-blind, randomized, cross-over, placebo-controlled comparison in skin responses induced by histamine iontophoresis.
Topics: Adult; Cetirizine; Cognition; Cross-Over Studies; Dibenzoxepins; Double-Blind Method; Female; Health | 2013 |
The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects.
Topics: Adolescent; Adult; Cetirizine; Cross-Over Studies; Double-Blind Method; Healthy Volunteers; Histamin | 2014 |
Long-term effects of pulsed high-intensity laser therapy in the treatment of post-burn pruritus: a double-blind, placebo-controlled, randomized study.
Topics: Adult; Burns; Cetirizine; Double-Blind Method; Female; Hand Strength; Humans; Laser Therapy; Male; M | 2017 |
Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis.
Topics: Adult; Anti-Inflammatory Agents; Cetirizine; Eosinophils; Female; Histamine H1 Antagonists, Non-Seda | 2008 |
Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu | 2009 |
A comparative analysis of cetirizine, gabapentin and their combination in the relief of post-burn pruritus.
Topics: Adolescent; Adult; Aged; Amines; Analgesics; Burns; Cetirizine; Child; Cyclohexanecarboxylic Acids; | 2011 |
Efficacy of Tripterygium hypoglaucum Hutch in adults with chronic urticaria.
Topics: Adult; Antipruritics; Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagon | 2011 |
Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life.
Topics: Adolescent; Adult; Anti-Allergic Agents; Cetirizine; Dibenzoxepins; Double-Blind Method; Female; His | 2013 |
Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis: a patient- and examiner-blinded, randomized, placebo-controlled, crossover trial.
Topics: Acupuncture Therapy; Administration, Oral; Cetirizine; Cross-Over Studies; Dermatitis, Atopic; Doubl | 2012 |
A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus.
Topics: Adult; Analgesics; Anti-Allergic Agents; Burns; Cetirizine; Coconut Oil; Double-Blind Method; Female | 2013 |
The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers.
Topics: Adult; Asian People; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2013 |
A multicenter, double-blind, randomized, noninferiority comparison of 14 days' treatment with oral olopatadine 10 mg or cetirizine 10 mg in Chinese adults with cutaneous pruritus.
Topics: Adult; Anti-Allergic Agents; Asian People; Cetirizine; Dibenzoxepins; Double-Blind Method; Female; H | 2013 |
Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy.
Topics: Adult; Cetirizine; Female; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Indoles; Male; | 2003 |
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.
Topics: Adult; Anti-Allergic Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Erythema; Histamin | 2003 |
Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism.
Topics: Acetates; Adolescent; Adult; Asthma; Cetirizine; Cyclopropanes; Double-Blind Method; Drug Synergism; | 2004 |
Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients.
Topics: Adult; Aged; Antipruritics; Cetirizine; Female; Histamine; Histamine H1 Antagonists; Humans; Indoles | 2004 |
Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study.
Topics: Adolescent; Adult; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; | 2005 |
Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Cetirizine; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; | 2006 |
Levocetirizine for treatment of immediate and delayed mosquito bite reactions.
Topics: Adult; Aedes; Animals; Cetirizine; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Ant | 2006 |
Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial.
Topics: Administration, Oral; Adult; Antipruritics; Cetirizine; Chemical Warfare Agents; Chronic Disease; Do | 2007 |
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental | 1997 |
Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses.
Topics: Adolescent; Adult; Aged; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; | 1998 |
Role of antigen-induced cytokine release in atopic pruritus.
Topics: Adolescent; Adult; Allergens; Animals; Anti-Allergic Agents; Antigens; Cetirizine; Cross-Over Studie | 1998 |
Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients.
Topics: Acetylcholine; Adult; Cetirizine; Cholinergic Agents; Cross-Over Studies; Dermatitis, Atopic; Double | 1999 |
Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study.
Topics: Adolescent; Adult; Cetirizine; Chromatography, Liquid; Histamine H1 Antagonists; Humans; Kidney Fail | 2001 |
Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy.
Topics: Adult; Animals; Butyrophenones; Cetirizine; Conscious Sedation; Cross-Over Studies; Culicidae; Doubl | 2002 |
Pharmacologic modulation by cetirizine-2 HCl of cutaneous reactions and pruritus in man after experimental mosquito bites.
Topics: Animals; Cetirizine; Culicidae; Double-Blind Method; Histamine H1 Antagonists; Humans; Hydroxyzine; | 1989 |
23 other studies available for cetirizine and Itching
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.
Topics: Adult; Cetirizine; Dose-Response Relationship, Drug; Female; Histamine H1 Antagonists, Non-Sedating; | 2020 |
The short-term effect of levocetirizine on quality of life, stress, and depression in itchy psoriasis patients.
Topics: Adult; Cetirizine; Depression; Histamine H1 Antagonists, Non-Sedating; Humans; Middle Aged; Pruritus | 2020 |
Development of nanoemulsion gel drug delivery systems of cetirizine; factorial optimisation of composition,
Topics: Adolescent; Adult; Animals; Cetirizine; Drug Compounding; Drug Delivery Systems; Drug Liberation; Em | 2020 |
A dermatosis of pregnancy.
Topics: Adult; Anti-Allergic Agents; Biopsy; Cetirizine; Drug Administration Routes; Female; Glucocorticoids | 2017 |
Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma.
Topics: Adult; Cetirizine; Deamino Arginine Vasopressin; Diabetes Insipidus; Drug Eruptions; Erdheim-Chester | 2014 |
Pruritic erythematous plaques.
Topics: Aged; Anti-Allergic Agents; Cetirizine; Diagnosis, Differential; Diphenhydramine; Female; Humans; My | 2014 |
[Clinical effects of gabapentin on the treatment of pruritus of scar resulting from deep partial-thickness burn].
Topics: Amines; Analgesics; Ascorbic Acid; Burns; Cetirizine; Cicatrix; Cyclohexanecarboxylic Acids; Gabapen | 2015 |
A case of levocetirizine-induced liver injury.
Topics: Cetirizine; Chemical and Drug Induced Liver Injury; Histamine H1 Antagonists, Non-Sedating; Humans; | 2016 |
Participation of histamine H3 receptors in experimental allergic rhinitis of mice.
Topics: Animals; Anti-Allergic Agents; Cetirizine; Chemotaxis, Leukocyte; Disease Models, Animal; Dose-Respo | 2008 |
Participation of proteinase-activated receptor-2 in passive cutaneous anaphylaxis-induced scratching behavior and the inhibitory effect of tacrolimus.
Topics: Animals; Antibodies, Monoclonal; Antipruritics; Behavior, Animal; Cetirizine; Dose-Response Relation | 2009 |
Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice.
Topics: Animals; Cetirizine; Dinoprostone; Dose-Response Relationship, Drug; Drug Interactions; Hydroxyurea; | 2009 |
[Cetirizine hepatotoxicity].
Topics: Adult; Cetirizine; Chemical and Drug Induced Liver Injury; Conjunctivitis, Allergic; Female; Histami | 2011 |
Treatment of generalized pruritus: comparison of narrowband ultraviolet-B with oral cetirizine.
Topics: Administration, Oral; Anti-Allergic Agents; Cetirizine; Combined Modality Therapy; Female; Humans; M | 2011 |
An open clinical trial on the efficacy of cetirizine hydrochloride in the management of allergic pruritus in cats.
Topics: Administration, Oral; Animals; Antipruritics; Cat Diseases; Cats; Cetirizine; Female; Hypersensitivi | 2012 |
Investigation of an unexplained skin disorder in a prison clinic in the Netherlands in 2002.
Topics: Abdomen; Adult; Ambulatory Care Facilities; Anti-Allergic Agents; Back; Bedding and Linens; Cetirizi | 2003 |
Treatment of canine atopic dermatitis with cetirizine, a second generation antihistamine: a single-blinded, placebo-controlled study.
Topics: Administration, Oral; Animals; Cetirizine; Cross-Over Studies; Dermatitis, Atopic; Dog Diseases; Dog | 2004 |
Participation of chemical mediators in the development of experimental allergic conjunctivitis in rats.
Topics: Administration, Oral; Animals; Carbazoles; Cetirizine; Conjunctivitis, Allergic; Disease Models, Ani | 2004 |
Recurrent, pruritic dermal plaques and bullae. Diagnosis: eosinophilic cellulitis (Wells syndrome).
Topics: Administration, Oral; Aged, 80 and over; Anti-Allergic Agents; Anti-Inflammatory Agents; Blister; Ce | 2007 |
[Allergic reactions of skin and mucous membranes. New findings about etiology, pathology and therapy].
Topics: Cetirizine; Dermatitis; Dermatitis, Atopic; Eosinophils; Granulocytes; Histamine Antagonists; Humans | 1994 |
Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch?
Topics: Adult; Cetirizine; Female; Histamine; Histamine H1 Antagonists; Humans; Indoles; Iontophoresis; Male | 1997 |
Antihistamines for atopic dermatitis.
Topics: Adolescent; Adult; Aged; Antipruritics; Cetirizine; Child; Clemastine; Dermatitis, Atopic; Double-Bl | 2000 |
Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study.
Topics: Adult; Cetirizine; Dermatitis, Atopic; Female; Histamine; Histamine H1 Antagonists; Humans; Inflamma | 2000 |